The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its binding ability in a functional ELISA.
Immobilized ab182688 at 10 μg/ml (100 μl/well) can bind Human TNFSF11 Fc Chimera with a linear range of 4-256 ng/ml.
< 1.000 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Store at -80°C. Reconstitute for long term storage.
pH: 7.4 Constituents: 95% PBS, 5% Trehalose
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended to reconstitute the lyophilized product in sterile deionized water to a final concentration of 1 mg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.
Osteoclastogenesis inhibitory factor
TNF receptor superfamily member 11b
Tumor necrosis factor receptor superfamily member 11B
Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in disease
Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
Contains 2 death domains. Contains 4 TNFR-Cys repeats.
N-glycosylated. Contains sialic acid residues. The N-terminus is blocked.